TQB2825 / Sino Biopharm - LARVOL DELTA

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma (clinicaltrials.gov) - P3 | N=228 | Not yet recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

New P3 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies (clinicaltrials.gov) - P1 | N=75 | Not yet recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

New P1 trial • Hematological Malignancies • Oncology

TQB2825, A NOVEL 2:1 STRUCTURED CD20XCD3 BISPECIFIC ANTIBODY,IN THE RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EHA 2025) - P1 | "TQB2825 demonstrated favorable tolerability and efficacy in patients with r/r FL, and the addition of rituximab pretreatment significantly improved its safety. TQB2825 has demonstrated a high response rate in heavily pretreated r/r FL patients, even in patients with bulky disease or those who have undergone CAR-T therapy. These results suggest that TQB2825 is a promising treatment option for patients with r/r FL, supporting further research."

Anemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P2 | N=55 | Recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P2 | N=55 | Not yet recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=150 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1/2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • CD20